The CD9+ CD11b- HLA-DR- immunophenotype can be used to diagnose acute promyelocytic leukemia

Int J Lab Hematol. 2019 Apr;41(2):168-175. doi: 10.1111/ijlh.12929. Epub 2018 Oct 13.

Abstract

Objective: To investigate the immunophenotypic characteristics of acute promyelocytic leukemia (APL) and explore the sensitivity and specificity of various antibody combinations for the timely and accurate diagnosis APL.

Methods: A retrospective analysis was performed using morphological, immunological, genetic, and molecular biological data from 92 patients diagnosed with APL and 190 controls diagnosed with non-APL acute myeloid leukemia.

Results: For APL diagnosis, the CD9/CD11b/human leukocyte antigen (HLA)-DR antibody combination had 85% sensitivity and 95% specificity, AUC = 0.85. However, the sensitivity and specificity were 39% and 92%, AUC = 0.65, respectively, for the HLA-DR/CD34/CD117 combination, and 80% and 80%, AUC = 0.80, respectively for the CD11b/HLA-DR combination. Significant differences were observed between the different antibody combinations.

Conclusions: The CD9/CD11b/HLA-DR antibody combination displays high sensitivity and specificity and can be used to diagnose APL.

Keywords: acute promyelocytic leukemia,; flow cytometry; immunophenotype.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD19 / blood*
  • CD11b Antigen / blood*
  • Female
  • HLA-DR Antigens / blood*
  • Humans
  • Immunophenotyping*
  • Leukemia, Promyelocytic, Acute* / blood
  • Leukemia, Promyelocytic, Acute* / diagnosis
  • Male
  • Middle Aged
  • Neoplasm Proteins / blood*

Substances

  • Antigens, CD19
  • CD11b Antigen
  • CD19 molecule, human
  • HLA-DR Antigens
  • ITGAM protein, human
  • Neoplasm Proteins